Study Notes

One note per topic: the must-know facts, the rules in plain English, worked examples and the traps that cost marks. The must-know list, the opening sections and the traps of every note are free; Premium unlocks the rest.

Start here

Hypertension & Dyslipidemia

1A Clinical Care · 3 min

18 notes, 36 min of reading. Start here and work down the list.

Read →

1A Clinical Care

10 notes

Hypertension & Dyslipidemia3 min · Hypertension and lipid management are core Part I clinical topics: expect patient scenarios asking for the next drug, a target, a monitoring step or an interaction, using Hypertension Canada's 2025 primary care guideline and the 2021 CCS dyslipidemia guidelines.
Heart Failure, AF, CAD & Anticoagulation3 min · Heart failure, atrial fibrillation, coronary disease and anticoagulation produce some of the highest-stakes Part I items: drug selection, DOAC dosing, warfarin interactions and secondary prevention, with Canadian (CCS, Thrombosis Canada) guidance and product monographs.
Diabetes, Thyroid, Bone & Hormones2 min · Endocrine items cover diabetes therapy and safety (hypoglycemia, sick days, renal dosing), thyroid replacement, osteoporosis, contraception and menopause, applying Diabetes Canada, ATA, Osteoporosis Canada and SOGC guidance.
Asthma, COPD & Smoking Cessation2 min · Respiratory items test the CTS 2021 asthma and 2023 COPD updates, inhaler technique, exacerbation action, smoking cessation pharmacotherapy and allergic rhinitis, often in patient cases with control criteria to interpret.
Infectious Diseases & Immunization2 min · Infection items test first-line antibiotic choice by site and patient, stewardship (when not to treat), key interactions and adverse effects, STI treatment and the Canadian Immunization Guide, using AMMI Canada, Bugs & Drugs, PHAC and NACI sources.
Neurology & Mental Health2 min · Neuro-psych items cover depression (CANMAT 2023), anxiety, bipolar disorder and lithium, antipsychotic safety and clozapine, ADHD, insomnia, opioid and alcohol use disorder, epilepsy, Parkinson disease, dementia and migraine, with many safety-critical interactions.
GI, Renal & Hepatic Disorders2 min · GI, renal and hepatic items test reflux and ulcer care, IBD and IBS, constipation and nausea, CKD drug stewardship, electrolyte problems and dosing in liver disease, often as medication reviews in older adults.
Pain, Musculoskeletal & Rheumatology2 min · Pain and rheumatology items test analgesic choice and limits, opioid safety under the 2017 Canadian guideline, neuropathic pain, osteoarthritis, rheumatoid arthritis drug monitoring and gout management.
Self-care & Minor Ailments2 min · Self-care items test when to treat with nonprescription products and when to refer: coughs and colds, eye and ear complaints, skin conditions, GI symptoms, emergency contraception, vaginal symptoms, pediatric fever and natural health products.
Special Populations & Other Therapeutics2 min · These items apply therapeutics to pediatrics, older adults, pregnancy and lactation, oncology supportive care, urology, ophthalmology and transplant medicine, where the same drug can be right for one patient and harmful for another.

1B Distribution

3 notes

2 Knowledge & Expertise

1 note

Evidence-based Practice & Drug Information2 min · Knowledge and Expertise items test critical appraisal and biostatistics: study designs and bias, NNT and risk measures, confidence intervals and p-values, diagnostic test statistics, meta-analysis, pharmacoeconomics and answering drug information requests.

3 Communication & Collaboration

1 note

Communication, Collaboration & Documentation2 min · Communication and Collaboration is about 4% of Part I but much more of the OSCE. MCQ items test teach-back, motivational interviewing, interprofessional communication, documentation, medication reconciliation and patient-centred conversations.

4 Leadership & Stewardship

1 note

Public Health & Stewardship1 min · Leadership and Stewardship (about 3%) items test the pharmacist's role in population health: antimicrobial stewardship, screening, vaccination programs, harm reduction, health equity, travel health and safe medication disposal.

5 Professionalism

2 notes

Educational practice material for exam preparation only. Not medical advice and not a substitute for current product monographs, clinical guidelines or professional judgement. Questions have not yet been reviewed by a licensed pharmacist.